The company is currently expanding on research performed by the founders of the company, where a new paradigm of pathological calcification was discovered.
This led to the search for therapies that enhance H2S in tissues by allosteric modulation of the enzyme CSE, one of three key enzymes regulating cellular H2S production.
The concept of allosteric modulation permits the upregulation of cellular H2S production at near physiological levels and avoids the potential toxicities that could arise by administering exogenous H2S to the subject. The company’s research has led to the discovery of a novel family of molecules that act as positive allosteric modulators (PAM) on CSE and upregulate H2S production significantly. These compounds are undergoing further medicinal chemistry development to bring them to market.
Fundraising from angel investors and private equity for development from 2024 onwards.
| 1 mio | 2021-2023 Financial support including Innosuisse funding |
Published in Pharmacological Research in September 2025 - the first CSEPAM and its binding to CSE and its effect on H2S production as well as...
Dr Ilaria Bernabei and the SULFISCON founders published this review which details the mechanisms leading to pathological calcification in...
Dr Sonia Nasi published her findings on the role of CSE in pathologic cartilage and tendon calcification and how a CSE activator can prevent this....